Julie Olsson

1.8k total citations · 1 hit paper
15 papers, 1.1k citations indexed

About

Julie Olsson is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Immunology. According to data from OpenAlex, Julie Olsson has authored 15 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 8 papers in Physiology and 4 papers in Immunology. Recurrent topics in Julie Olsson's work include Asthma and respiratory diseases (7 papers), Respiratory and Cough-Related Research (5 papers) and IL-33, ST2, and ILC Pathways (4 papers). Julie Olsson is often cited by papers focused on Asthma and respiratory diseases (7 papers), Respiratory and Cough-Related Research (5 papers) and IL-33, ST2, and ILC Pathways (4 papers). Julie Olsson collaborates with scholars based in United States, Japan and United Kingdom. Julie Olsson's co-authors include Michael K. Gould, Cécile Holweg, John G. Matthews, Wendy S. Putnam, Phillip E. Korenblat, Nicola A. Hanania, Sarah Gray, Saloumeh K Fischer, Kun Peng and Kenneth R. Chapman and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, CHEST Journal and European Respiratory Journal.

In The Last Decade

Julie Olsson

15 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials

2016 350 citations Nicola A. Hanania, Phillip E. Korenblat et al. The Lancet Respiratory Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Julie Olsson United States	11	597	589	286	212	179	15	1.1k
May Mo United States	9	508 0.9×	842 1.4×	374 1.3×	414 2.0×	174 1.0×	21	1.3k
Patricia Rohane United States	9	266 0.4×	436 0.7×	360 1.3×	226 1.1×	46 0.3×	10	981
Necdet B. Gunsoy United Kingdom	13	655 1.1×	846 1.4×	213 0.7×	196 0.9×	108 0.6×	33	1.1k
Natasha Purington United States	14	108 0.2×	300 0.5×	116 0.4×	593 2.8×	118 0.7×	54	1.0k
J. Thirlwell United Kingdom	12	1.3k 2.1×	1.7k 2.9×	243 0.8×	1.0k 4.8×	31 0.2×	17	1.9k
Brian D. Modena United States	13	206 0.3×	389 0.7×	243 0.8×	94 0.4×	31 0.2×	26	770
Lynn E. Katz United States	3	1.2k 2.0×	1.6k 2.7×	429 1.5×	378 1.8×	15 0.1×	8	1.8k
Gun Almqvist Sweden	12	455 0.8×	790 1.3×	306 1.1×	265 1.3×	11 0.1×	23	972
JingYuan Feng United States	10	327 0.5×	603 1.0×	367 1.3×	109 0.5×	7 0.0×	11	865
Katerina Samara Greece	15	805 1.3×	348 0.6×	102 0.4×	50 0.2×	49 0.3×	35	1.0k

Countries citing papers authored by Julie Olsson

Since Specialization

Citations

This map shows the geographic impact of Julie Olsson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Olsson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Olsson more than expected).

Fields of papers citing papers by Julie Olsson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Olsson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Olsson. The network helps show where Julie Olsson may publish in the future.

Co-authorship network of co-authors of Julie Olsson

This figure shows the co-authorship network connecting the top 25 collaborators of Julie Olsson. A scholar is included among the top collaborators of Julie Olsson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Olsson. Julie Olsson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Brightling, Christopher E., James D. Chalmers, Parameswaran Nair, et al.. (2023). ALIENTO and ARNASA: Study designs of two randomised, double-blind, placebo-controlled trials of astegolimab in patients with COPD. PA1292–PA1292. 2 indexed citations

Li, Qingling, Weng Ruh Wong, Arindam Chakrabarti, et al.. (2021). Lysophosphatidic acid species are associated with exacerbation in chronic obstructive pulmonary disease. BMC Pulmonary Medicine. 21(1). 301–301. 4 indexed citations

Maher, Toby M., Ulrich Costabel, Marilyn K. Glassberg, et al.. (2020). Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis. European Respiratory Journal. 57(2). 1902442–1902442. 51 indexed citations

Bauer, Rebecca N., Xiaoying Yang, Tracy Staton, et al.. (2019). Seasonal variability of lung function and Asthma Quality of Life Questionnaire Scores in adults with uncontrolled asthma. BMJ Open Respiratory Research. 6(1). e000406–e000406. 6 indexed citations

Varughese, Rachel, Barney Montgomery, Cécile Holweg, et al.. (2018). Serum periostin levels in adults of Chinese descent: an observational study. Allergy Asthma and Clinical Immunology. 14(1). 87–87. 16 indexed citations

Zhu, Rui, Nathanael L. Dirks, Shweta Vadhavkar, et al.. (2017). Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma. Pulmonary Pharmacology & Therapeutics. 46. 88–98. 16 indexed citations

Лещенко, И. В., Karl Yen, Cécile Holweg, et al.. (2017). Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids. Respiratory Medicine. 134. 143–149. 46 indexed citations

Hanania, Nicola A., Phillip E. Korenblat, Kenneth R. Chapman, et al.. (2016). Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. The Lancet Respiratory Medicine. 4(10). 781–796. 350 indexed citations breakdown →

Hanania, Nicola A., Phillip E. Korenblat, Kenneth R. Chapman, et al.. (2016). LATE-BREAKING ABSTRACT: LAVOLTA I and II: Results of 2 phase III studies to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma. OA1975–OA1975. 1 indexed citations

10.

Hanania, Nicola A., Michael Noonan, Jonathan Corren, et al.. (2015). Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 70(8). 748–756. 299 indexed citations

11.

Simrén, Magnus, Lena Öhman, Julie Olsson, et al.. (2010). Probiotics in irritable bowel syndrome: underachievers or underpowered? authors’ reply. Alimentary Pharmacology & Therapeutics. 31(8). 923–924. 21 indexed citations

12.

Olsson, Julie, et al.. (2009). Timeliness of care in patients with lung cancer: a systematic review. Thorax. 64(9). 749–756. 153 indexed citations

13.

Schultz, Ellen, Adam A. Powell, Alex McMillan, et al.. (2008). Hospital Characteristics Associated with Timeliness of Care in Veterans with Lung Cancer. American Journal of Respiratory and Critical Care Medicine. 179(7). 595–600. 42 indexed citations

14.

Gould, Michael K., et al.. (2008). Timeliness of Care in Veterans With Non-small Cell Lung Cancer. CHEST Journal. 133(5). 1167–1173. 67 indexed citations

15.

Olsson, Julie, Roham T. Zamanian, Jeffrey A. Feinstein, & Ramona L. Doyle. (2005). Surgical and Interventional Therapies for Pulmonary Arterial Hypertension. Seminars in Respiratory and Critical Care Medicine. 26(4). 417–428. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact